Difference between revisions of "Cabozantinib (Cometriq)"
(FDA approval) |
m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Non-small cell lung cancer]] | ||
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
*[[Renal cancer]] | *[[Renal cancer]] | ||
| Line 40: | Line 41: | ||
[[Category:TEK inhibitors]] | [[Category:TEK inhibitors]] | ||
[[Category:VEGF inhibitors]] | [[Category:VEGF inhibitors]] | ||
| + | |||
| + | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
[[Category:Renal cancer medications]] | [[Category:Renal cancer medications]] | ||
[[Category:Thyroid cancer medications]] | [[Category:Thyroid cancer medications]] | ||
[[Category:Drugs FDA approved in 2012]] | [[Category:Drugs FDA approved in 2012]] | ||
Revision as of 13:10, 30 November 2016
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits RET, MET/c-Met, VEGFR-1, VEGFR-2, VEGFR-3, KIT, TRKB, FLT-3, AXL, and TIE-2.[1][2][3][4][5][6]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1][4]
Diseases for which it is used
Patient drug information
- Cabozantinib (Cometriq) package insert pages 20-24[1] (the numbering for the PDF is off, so in some PDF viewers, the patient information is on pages 27-31)
- Cabozantinib (Cabometyx) package insert[4]
- Cabozantinib (Cometriq) patient drug information (Chemocare)[7]
- Cabozantinib (Cometriq) patient drug information (UpToDate)[8]
History of changes in FDA indication
- 11/29/2012: FDA approved (as Cometriq) for treatment of "progressive metastatic medullary thyroid cancer (MTC)"
- 4/25/2016: FDA approved (as Cabometyx) "for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy."
Also known as
XL184 or XL-184. Cometriq is the brand name for cabozantinib's medullary thyroid cancer indication. Cabometyx is the brand name for cabozantinib's renal cell carcinoma indication.
References
- ↑ 1.0 1.1 1.2 Cabozantinib (Cometriq) package insert
- ↑ Cabozantinib (Cometriq) package insert (locally hosted backup)
- ↑ Cometriq manufacturer's website
- ↑ 4.0 4.1 4.2 Cabozantinib (Cabometyx) package insert
- ↑ Cabozantinib (Cabometyx) package insert (locally hosted backup)
- ↑ Cabometyx manufacturer's website
- ↑ Cabozantinib (Cometriq) patient drug information (Chemocare)
- ↑ Cabozantinib (Cometriq) patient drug information (UpToDate)
- Drug index
- Chemotherapy
- Oral chemotherapy
- Kinase inhibitors
- AXL inhibitors
- FLT3 inhibitors
- KIT inhibitors
- MET inhibitors
- NTRK2 inhibitors
- RET inhibitors
- TEK inhibitors
- VEGF inhibitors
- Non-small cell lung cancer medications
- Prostate cancer medications
- Renal cancer medications
- Thyroid cancer medications
- Drugs FDA approved in 2012